C

Chase Medical Research, LLC | Waterbury, MA

Research site
(Unclaimed)
Location
500 Chase Parkway 3rd floor, Waterbury, Massachusetts, United States of America
Site insights

Top conditions

Type 2 Diabetes Mellitus (19 trials)

Diabetes Mellitus (19 trials)

Overweight (10 trials)

Obesity (9 trials)

Kidney Diseases (7 trials)

Top treatments

Tirzepatide
LY3298176
Bapineuzumab
Retatrutide
LY3437943
Finerenone
Naltrexone
BI 685509
Hydrocodone Bitartrate
Tolterodine

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

21 of 69
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)

The main purpose of this study is to determine the efficacy and safety of insulin efsitora alfa (LY3209590) administered weekly using a fixed dose es...

Active, not recruiting
Type 2 Diabetes
T2D
Drug: Insulin Glargine
Drug: Insulin Efsitora Alfa

The reason for this study is to see if the study drug insulin efsitora alfa (LY3209590) is safe and effective in participants with Type 2 diabetes th...

Active, not recruiting
Type 2 Diabetes
Drug: Insulin Efsitora Alfa
Drug: Insulin Degludec

The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabet...

Enrolling
Obesity
Type 2 Diabetes
Drug: Tirzepatide
Drug: Placebo

This a multicenter, Phase 2b, double-blind, placebo-controlled, parallel group study to provide data on efficacy and safety of LY3561774 administered...

Active, not recruiting
Metabolic Diseases
Lipid Metabolism Disorders
Drug: Placebo
Drug: LY3561774

The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master pr...

Enrolling
Overweight
Knee Pain Chronic
Drug: Retatrutide
Drug: Placebo

The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiov...

Enrolling
Obesity
Cardiovascular Diseases
Drug: Placebo
Drug: Retatrutide

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have o...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: Retatrutide

The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight a...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: Retatrutide

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardio...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Tirzepatide
Drug: Dulaglutide

This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weig...

Active, not recruiting
Overweight
Obesity
Drug: Tirzepatide
Drug: Placebo
Locations recently updated

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide

The purpose of this is study is to compare the efficacy of BHV-3500 (zavegepant) to placebo as a preventive treatment for migraine, as measured by th...

Active, not recruiting
Migraine
Drug: Placebo
Drug: BHV-3500 (zavegepant)

The purpose of this study is to evaluate the safety and immunogenicity in parallel of heptavalent mRNA-1975 and monovalent mRNA-1982 against Lyme dis...

Active, not recruiting
Lyme Disease
Biological: mRNA-1975
Biological: Placebo

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

Finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of mineralocorticoid receptor is known...

Enrolling
Chronic Kidney Disease
Type 2 Diabetes Mellitus
Drug: Finerenone (BAY94-8862 ) 20 mg
Drug: Empagliflozin Placebo

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling
Obesity
Drug: Placebo
Drug: survodutide

Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial treatment, finere...

Active, not recruiting
Non-diabetic Chronic Kidney Disease
Drug: Finerenone (BAY94-8862)
Drug: Placebo

VLA15-221 is a Phase 2 study, which will be conducted in two parts: Main Study Phase (Part A) and Booster Phase (Part B). The study will compare the...

Active, not recruiting
Lyme Borreliosis
Biological: Placebo
Biological: VLA15

The purpose of this study is to further evaluate the long-term safety and tolerability of daily dosing of rimegepant for the prevention of episodic m...

Active, not recruiting
Photophobia
Migraine
Drug: Rimegepant

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Inclisiran sodium 300 mg

Trial sponsors

Lilly logo

Lilly (22 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems